| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
25001 |
| Drug |
Maralixibat |
| Brand |
Livmarli® |
| Indication |
Maralixibat (Livmarli®) is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. |
| Rapid review commissioned |
06/01/2025 |
| Rapid review completed |
04/02/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of maralixibat compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/02/2025 |
| Pre-submission consultation with Applicant |
09/04/2025 |
| Full submission received from Applicant |
13/08/2025 |
